Thomas U Schulz, Sarah Zierold, Michael M Sachse, Giulia Pesch, Dirk Tomsitz, Katharina Schilbach, Katharina C Kähler, Lars E French, Lucie Heinzerling
{"title":"“停止检查点抑制剂治疗后持续免疫相关不良事件:患病率和对患者健康相关生活质量的影响”[J].中华癌症杂志,2016(6):88-99。","authors":"Thomas U Schulz, Sarah Zierold, Michael M Sachse, Giulia Pesch, Dirk Tomsitz, Katharina Schilbach, Katharina C Kähler, Lars E French, Lucie Heinzerling","doi":"10.1016/j.ejca.2025.115236","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":" ","pages":"115236"},"PeriodicalIF":7.6000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to \\\"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life\\\" [Eur J Cancer 176 (2022) 88-99].\",\"authors\":\"Thomas U Schulz, Sarah Zierold, Michael M Sachse, Giulia Pesch, Dirk Tomsitz, Katharina Schilbach, Katharina C Kähler, Lars E French, Lucie Heinzerling\",\"doi\":\"10.1016/j.ejca.2025.115236\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\" \",\"pages\":\"115236\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejca.2025.115236\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejca.2025.115236","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Corrigendum to "Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life" [Eur J Cancer 176 (2022) 88-99].
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.